Why did HOTH's EPS remain stagnant in recent quarters?

The EPS of HOTH remained stagnant in recent quarters due to a combination of factors:

1. **Revenue and Net Income**: The company reported a net loss of $2.38 million for the quarter ended December 31, 2024. This net loss, coupled with no reported revenue for the same period, indicates that the company's operations were not profitable, which directly impacts the EPS.
2. **Clinical Trial Progress**: HOTH has been actively involved in clinical trials, as evidenced by the expansion of its Phase 2a clinical trial for HT-001 and the partnership with Aronnax for HT-KIT. These activities are likely to be costly, impacting the company's financials and potentially affecting profitability.
3. **Patent Securing and R&D**: The company secured a U.S. patent for its Alzheimer's disease therapeutic candidate, HT-ALZ, which is a significant achievement. However, the costs associated with securing patents and ongoing research and development (R&D) efforts can be substantial and may impact the EPS.
4. **Stock Price and Nasdaq Compliance**: HOTH faces challenges in maintaining the Nasdaq Capital Market's minimum bid price of $1.00 per share. The company has been granted a 180-day period to regain compliance, which could impact investor confidence and financial operations.

In conclusion, the stagnant EPS of HOTH can be attributed to the company's financial losses, clinical trial expenses, patent securing costs, and the need to comply with Nasdaq listing requirements. These factors combined create a challenging environment for the company's financial performance in the near term.